0001426332 2021-01-01 2021-06-30 0001426332 2021-08-02 shares CA true Q2 0001426332 --12-31 10-Q/A true 2021-06-30 2021 false 001-38853 NGM BIOPHARMACEUTICALS, INC. DE 26-1679911 333 Oyster Point Boulevard South San Francisco 94080 650 243-5555 Common Stock, par value $0.001 per share NGM NASDAQ Yes Yes Accelerated Filer false true false false 77338144 EXPLANATORY NOTE We are filing this Amendment No. 1 to Quarterly Report on Form 10-Q/A (this “Amendment”) to amend our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on August 5, 2021 (the “10-Q”). This Amendment is being filed solely to refile the certifications of our principal executive officer and principal financial officer as exhibits to this Amendment as required pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities and Exchange Act of 1934. No attempt has been made in this Amendment to otherwise modify or update the other disclosures presented in the 10-Q. This Amendment does not reflect events occurring after the filing of the original 10-Q (i.e., those events occurring after August 5, 2021) or modify or update those disclosures that may be affected by subsequent events. Such subsequent matters are addressed in subsequent reports filed with the SEC. Accordingly, this Amendment should be read in conjunction with the 10-Q and our other filings with the SEC.